Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues
Jun 28
U.S. Biotech Industry Analysis
UpdatedJun 29, 2024
DataAggregated Company Financials
Companies567
- 7D-0.7%
- 3M-3.4%
- 1Y10.0%
- YTD1.5%
Last week, the Biotech industry hasn't moved much but Alnylam Pharmaceuticals is up 47% in that time. The past year has been better, since the industry has gained 10.0% in that time. Looking forward, earnings are forecast to grow by 24% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 29 Jun 2024 | US$1.1t | US$164.4b | -US$28,157,592,218.37 | 28.5x | -40.7x | 7x |
| Mon, 27 May 2024 | US$1.1t | US$164.6b | -US$26,653,350,594.72 | 23.8x | -42.2x | 6.8x |
| Wed, 24 Apr 2024 | US$1.1t | US$164.3b | -US$23,439,543,461.97 | 20.4x | -46.7x | 6.7x |
| Fri, 22 Mar 2024 | US$1.2t | US$164.3b | -US$23,898,885,613.21 | 21.6x | -48.8x | 7.1x |
| Sun, 18 Feb 2024 | US$1.2t | US$169.1b | -US$20,519,191,458.58 | 15.7x | -56.9x | 6.9x |
| Tue, 16 Jan 2024 | US$1.4t | US$204.8b | -US$22,498,525,782.00 | 18.8x | -63.9x | 7x |
| Thu, 14 Dec 2023 | US$1.3t | US$204.7b | -US$22,099,611,280.00 | 19.6x | -59.9x | 6.5x |
| Sat, 11 Nov 2023 | US$1.2t | US$204.5b | -US$22,053,784,561.00 | 18.5x | -54.1x | 5.8x |
| Mon, 09 Oct 2023 | US$1.3t | US$207.4b | -US$13,060,168,797.00 | 17.2x | -96.4x | 6.1x |
| Wed, 06 Sep 2023 | US$1.3t | US$207.5b | -US$12,513,012,217.00 | 17.2x | -102x | 6.2x |
| Fri, 04 Aug 2023 | US$1.1t | US$183.2b | -US$17,641,388,597.00 | 14.5x | -64.3x | 6.2x |
| Sun, 02 Jul 2023 | US$1.1t | US$186.2b | -US$16,042,400,813.00 | 13.7x | -70x | 6x |
| Tue, 30 May 2023 | US$1.1t | US$185.9b | -US$16,045,777,796.00 | 11.2x | -69.9x | 6x |
| Thu, 27 Apr 2023 | US$1.2t | US$198.5b | -US$3,096,107,692.00 | 12.8x | -375.3x | 5.9x |
| Sat, 25 Mar 2023 | US$1.1t | US$199.3b | -US$3,645,756,952.00 | 13.4x | -310.8x | 5.7x |
| Mon, 20 Feb 2023 | US$1.2t | US$202.6b | -US$64,851,937.00 | 16.5x | -17789.6x | 5.7x |
| Wed, 18 Jan 2023 | US$1.2t | US$203.6b | US$1.7b | 14.6x | 683.1x | 5.8x |
| Fri, 16 Dec 2022 | US$1.2t | US$203.3b | US$1.6b | 14.5x | 734.9x | 5.7x |
| Sun, 13 Nov 2022 | US$1.1t | US$202.2b | US$1.1b | 14.6x | 1045.5x | 5.5x |
| Tue, 11 Oct 2022 | US$1.0t | US$205.9b | US$5.4b | 14.9x | 192.3x | 5x |
| Thu, 08 Sep 2022 | US$1.0t | US$206.1b | US$6.0b | 14.5x | 169.1x | 5x |
| Sat, 06 Aug 2022 | US$1.1t | US$211.4b | US$8.8b | 16.7x | 125.7x | 5.3x |
| Mon, 04 Jul 2022 | US$1.1t | US$212.1b | US$11.0b | 15.8x | 95.4x | 5x |
| Wed, 01 Jun 2022 | US$1.0t | US$212.7b | US$11.2b | 15.2x | 89.5x | 4.7x |
| Fri, 29 Apr 2022 | US$1.1t | US$200.2b | US$8.5b | 17.2x | 123.1x | 5.2x |
| Sun, 27 Mar 2022 | US$1.3t | US$221.9b | US$11.4b | 18.9x | 111.3x | 5.7x |
| Tue, 22 Feb 2022 | US$1.2t | US$216.5b | US$5.6b | 21.8x | 216.6x | 5.6x |
| Thu, 20 Jan 2022 | US$1.3t | US$212.0b | US$2.5b | 23.2x | 505x | 5.9x |
| Sat, 18 Dec 2021 | US$1.5t | US$211.9b | US$3.1b | 26.1x | 466.7x | 6.9x |
| Mon, 15 Nov 2021 | US$1.5t | US$212.2b | US$3.9b | 27.1x | 376.7x | 6.9x |
| Wed, 13 Oct 2021 | US$1.5t | US$196.3b | -US$2,605,456,444.00 | 23.3x | -557.7x | 7.4x |
| Fri, 10 Sep 2021 | US$1.6t | US$196.4b | -US$2,275,254,373.56 | 21.1x | -695.3x | 8.1x |
| Sun, 08 Aug 2021 | US$1.6t | US$197.0b | -US$1,525,228,785.58 | 23.2x | -1033.1x | 8x |
Price to Earnings Ratio
-1810.8x
Current Industry PE
- Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 6.2x is lower than the industry's current PS ratio of 7.0x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Revenues have also declined 5.8% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 0.04% | |
| Healthcare | -0.40% | |
| Biotech | -0.75% | |
| Biotech | -0.75% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | US$243.00 | 46.7% +US$9.8b | 27.9% | PS15.3x | |
| AMGN Amgen | US$312.45 | 1.4% +US$2.3b | 40.7% | PE44.5x | |
| ABBV AbbVie | US$171.52 | 0.7% +US$2.0b | 27.3% | PE50.9x | |
| SGEN Seagen | US$228.74 | 4.5% +US$1.8b | 76.5% | PS18.8x | |
| BIIB Biogen | US$231.82 | 3.5% +US$1.1b | -18.6% | PE28.9x |
